How It Works
CoQ10 is the electron carrier between Complex I/II and Complex III of the mitochondrial electron transport chain — the assembly line that makes ATP. It cycles through three redox states: fully oxidized (ubiquinone), partially reduced (ubisemiquinone), and fully reduced (ubiquinol). That cycling converts NADH and FADH2 into the proton gradient that drives ATP synthesis. Tissues with the highest energetic demand — heart, skeletal muscle, liver, kidneys — carry CoQ10 concentrations 2-10× higher than plasma. Endogenous biosynthesis declines with age, and several disease states correlate with reduced plasma CoQ10.
The clearest mechanism is statin-induced muscle pain. Statins inhibit HMG-CoA reductase, an enzyme shared by cholesterol and CoQ10 biosynthesis — both pathways start from mevalonate. Statin therapy reduces plasma CoQ10 by approximately −0.44 µmol/L across trials. The leading hypothesis is that this depletion drives skeletal muscle mitochondrial dysfunction in susceptible individuals. Supplementation directly reverses the depletion. That's why SAMS is the strongest CoQ10 evidence base.
The second mechanism is membrane antioxidant activity. Reduced ubiquinol regenerates vitamin E and directly quenches lipid peroxyl radicals — explaining the consistent reduction in oxidative-stress biomarkers across populations and the downstream reduction in inflammatory markers (CRP, IL-6, TNF-α). Effect sizes are modest but consistent in populations with existing oxidative-stress burden (cardiometabolic patients, aging adults, statin users) and negligible in healthy adults without that baseline.
The Debate
Does CoQ10 lower blood pressure?
Ho 2016 Cochrane (N=30, primary hypertension, 2 trials)
Effect on BP "uncertain — insufficient evidence."
vs
Zhao 2022 GRADE meta (N=1,831, cardiometabolic patients, 17 trials)
Significant SBP reduction of −3.65 mmHg, plateau at 200mg/day.
Population difference plus 6 years of accumulated evidence. Ho 2016 was isolated primary hypertension with 2 low-quality trials. Zhao 2022 was cardiometabolic disorder patients with higher baseline oxidative stress. The field matured dramatically between 2016 and 2022.
Does CoQ10 actually fix statin muscle pain?
Qu 2018 SAMS meta (N=575, 12 trials)
Muscle pain WMD −0.53.
vs
Banach 2025 SAMS meta (N=389, 7 trials)
Pain WMD −0.96, but 3 of 7 trials individually non-significant.
Both confirm direction. Magnitude varies with trial selection. Banach 2025 used standardised SAMS scoring; Qu 2018 included older lower-dose trials. SAMS is self-reported and placebo-responsive — that's why confidence intervals stay wide. The signal is real; the size depends on which trials you trust.
Does CoQ10 improve fertility outcomes?
Shang 2024 (intermediate endpoints)
Oocyte count and embryo quality improved in diminished ovarian reserve.
vs
Shang 2024 (hard endpoint)
Live birth rate NOT significantly improved.
Divergence between intermediate endpoints (oocyte, embryo) and the only endpoint patients actually care about (live birth). CoQ10 may improve cycle metrics without translating to babies. IVF clinics adopt it anyway because the downside is low — but patients paying £40-60/month should know the live-birth trial is still pending.
Honest Limitations
FORMULATION MISMATCH
Lab: 85% of meta-analytic evidence uses ubiquinone. Reality: consumers are upsold into ubiquinol at 2-4× the price without outcome-differential evidence. Direction: choose ubiquinone unless you fit a specific indication (age >60, polypharmacy, IVF protocol).
LABEL ACCURACY AND DEGRADATION
Lab: trials use laboratory-verified standardised extracts. Reality: CoQ10 is fat-soluble and heat-sensitive. A consumer-grade bottle on a shop shelf in summer can lose 20-50% of labelled potency within 6 months. Third-party testing has documented label/content discrepancies. Direction: buy from brands with published batch testing, or accept that the dose on the label is aspirational.
POPULATION MISMATCH
Lab: trials enrolled specific populations — statin users, heart failure patients, migraine sufferers, cardiometabolic patients. Reality: most consumers are healthy adults buying CoQ10 prophylactically because Instagram told them to. The evidence does not transfer from "100-300mg/day improves inflammation markers in cardiometabolic disease" to "100mg/day will make a healthy 30-year-old feel better." Direction: if you don't have a specific indication, the evidence for your use case is null.
The Nuance
CoQ10's clinical evidence partitions by indication, not by overall confidence. The supplement industry's job is to flatten that into a single confident "take CoQ10!" message. The honest read is the opposite: CoQ10 has unusually clear evidence for narrow use cases and unusually clear non-evidence for the broad consumer use case.
Real for narrow indications: Statin muscle pain has the strongest evidence. Heart failure as adjunct, cardiometabolic inflammation, migraine prophylaxis, and IVF ART all have moderate evidence at clinically defined doses. These are real use cases with real evidence.
Null for prophylactic use: No high-quality RCT supports healthy-adult prophylactic use. The clinical effects show up where there's something to correct — oxidative stress burden, statin depletion, mitochondrial dysfunction in disease states. Healthy adults under 60 don't have those baseline issues.
Cost-effectiveness: Ubiquinone at 100-200mg/day costs £8-15 per month — affordable for indicated populations. Ubiquinol costs £20-50 per month and is justified only if you're over 60, on multiple medications, or in an IVF protocol. MitoQ at £40-80 per month has no human outcome data and shouldn't be on the list.
Food alternatives: Dietary CoQ10 is typically 3-6mg per day from organ meats (heart, liver), fatty fish (sardines, mackerel), and beef. Reaching therapeutic doses through food is impossible. This is one of the few supplements where food-first cannot substitute for capsules in the indicated populations.
The clean clinical failure: The Negida 2016 Parkinson's meta is the cleanest bench-to-bedside failure in the file — high-dose trials up to 2400mg/day, halted by futility. Mechanistic plausibility (mitochondrial dysfunction in PD) did not translate to clinical efficacy. A useful reminder that "the mechanism makes sense" is not the same as "the supplement works."
